Clinical trials: Genitourinary Tract Infection
Bacteriuria
The Impact Of A Catheter Coating On Clinical Bacteriuria
A prospective multicentre randomized study to assess the impact of a catheter coating on clinical bacteriuria when compared to an uncoated foley catheter.
- Trial name
- NCT04461262
- Testing
- Camstent Coated Catheter, Standard Care
- Where
- 4 sites in United Kingdom
- Volunteers
- 272 people
- Sponsor
- Camstent Ltd.
Urinary Tract Infections
In Vitro Analysis of Human Urine With the CloudCath Device
This is a multi-center feasibility study to assess the in vitro function of the CloudCath Device that is being developed to derive clinically-relevant information from the optical characteristics of urine.
- Trial name
- NCT04950582
- Testing
- Spectral characteristics assessment
- Where
- Mexico
- Volunteers
- 500 people
- Sponsor
- CloudCath
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Urinary Tract Infections, Acute Pyelonephritis
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
- Trial name
- CERTAIN-1 (NCT03840148)
- Testing
- Cefepime/VNRX-5133 (taniborbactam), Meropenem
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 661 people
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Sepsis, Renal Failure
The Prevention of Failure to Rescue Using Early Warning Scoring
The purpose of this study is to assess if, compared with standard paper-based systems, an automated Early Warning System (EWS) resident in a spot check patient monitor, can help to identify deteriorating patients.
- Conditions
- Sepsis, Renal Failure, Pulmonary Edema, Cardio-pulmonary Arrest
- Trial name
- VitalCare (NCT01197326)
- Testing
- use of the MP5 EWS patient monitor
- Where
- Australia
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Fever, Respiratory Tract Infections
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
This is a retrospective, blinded, external validation study of a novel in-vitro diagnostic (IVD) assay that will include samples that were previously collected from febrile pediatric patients.
- Conditions
- Fever, Respiratory Tract Infections, Urinary Tract Infections, Gastroenteritis
- Trial name
- PATHFINDER (NCT01911143)
- Where
- 2 sites in Israel
- Volunteers
- 600 people
- Sponsor
- MeMed Diagnostics Ltd.
Urinary Tract Infections
Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)
To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI.
- Trial name
- FLUT (NCT00722735)
- Testing
- Finafloxacin, Ciprofloxacin
- Where
- 2 sites in Germany, Singapore
- Volunteers
- 36 people
- Sponsor
- MerLion Pharmaceuticals GmbH
Infections, Bacterial
Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor that is being developed for the treatment of uncomplicated urinary tract infections (UTIs; acute cystitis).
- Trial name
- NCT03568942
- Testing
- Gepotidacin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Urinary Tract Infection
Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)
The objective of the study is to assess safety and impact of a non-antibiotic therapy approach with Canephron® N in the management strategy of uncomplicated lower urinary tract infections (UTIs).
- Trial name
- NCT01478620
- Testing
- Canephron® N
- Where
- Ukraine
- Volunteers
- 125 people
- Sponsor
- Bionorica SE
Pneumonia, Pneumocystis Carinii, HIV Infections
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine
To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse…
- Trial name
- NCT00001990
- Testing
- Atovaquone
- Where
- United States
- Sponsor
- Glaxo Wellcome
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
Urinary Tract Infection Complicated, Acute Pyelonephritis
CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria
The purpose of this study is to evaluate the effects of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) compared to Meropenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis…
- Trial name
- PLEA (NCT03477422)
- Testing
- CSE-1034 (Ceftriaxone + Sulbactam + EDTA), Meropenem
- Where
- 17 sites in India
- Volunteers
- 230 people
- Sponsor
- Venus Remedies Limited
Urinary Tract Infection
Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults
The study aims to investigate bacteriological efficacy of a nitrofurantoin formulation given twice daily for seven days in the treatment of adult patients with microbiologically confirmed uncomplicated urinary tract infection.
- Trial name
- NCT01092351
- Testing
- Nitrofurantoin
- Where
- Mexico
- Volunteers
- 37 people
- Sponsor
- Mepha Ltd.
Urinary Tract Infections
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment…
- Trial name
- NCT07371429
- Testing
- Gepotidacin, SOC
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
This is a prospective, Phase 4, open label, multi-center study of the clinical and microbiologic efficacy of ciprofloxacin for the treatment of uncomplicated urinary tract infections in adult women.
- Trial name
- NCT03366207
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Iterum Therapeutics, International Limited
UTI's
An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement
This is a 6-month, three-arm randomized controlled trial evaluating the efficacy and safety of a dietary supplement drink mix on urinary health outcomes in adult females.
- Trial name
- NCT07453693
- Testing
- FLUSH
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bonafide Health
Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP
Reporting patterns and results of initial antibiotic treatment in patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including…
- Conditions
- Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and, Nosocomial Pneumonia (NP)
- Trial name
- RECOMMEND (NCT02364284)
- Where
- 27 sites in Brazil, France and 4 more
- Volunteers
- 1,322 people
- Sponsor
- Pfizer